Bosseau, Christian http://orcid.org/0000-0001-8245-9218
Donal, Erwan
Lund, Lars H.
Oger, Emmanuel
Hage, Camilla
Mulak, Geneviève
Daubert, Jean-Claude
Linde, Cecilia
Donal, Erwan
Lund, Lars H.
Leclercq, Christophe
de Groote, Pascal
Ennezat, Pierre-Vladimir
Lafitte, Stéphane
Réant, Patricia
Bauer, Fabrice
Derumeaux, Geneviève
Bergerot, Cyrille
de Place, Christian
Juillière, Yves
Selton-Suty, Christine
Logeart, Damien
Gueret, Pascal
Lim, Pascal
Trochu, Jean-Noël
Pirou, Nicolas
Habib, Gilbert
Tournoux, François
Haugen-Löfman, Ida
Edner, Magnus
Emtell, Hans
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study
https://doi.org/10.1007/s00380-016-0933-8
Funding for this research was provided by:
Medtronic Bakken Research Center
Société Française de Cardiologie
Article History
Received: 16 July 2016
Accepted: 9 December 2016
First Online: 27 December 2016
Compliance with ethical standards
:
: There are no commercial products involved in this study. However, to the extent that findings in KaRen may affect the use of heart failure drugs or devices, we disclose the following: LHL: research Grants and/or speaker and/or consulting honoraria from AstraZeneca, Novartis, Boston Scientific, and St Jude Medical; CL: principal investigator of REVERSE, a CRT study sponsored by Medtronic research Grants, speaker honoraria, and consulting fees from Medtronic, speaker honoraria, and consulting fees from St. Jude Medical; ED: speaker honoraria and consulting fees from Novartis, Bristol-Myer Squibb; JCD: research Grants, speaker honoraria, and consulting fees from Medtronic and St Jude Medical. All other authors have no conflict of interest to declare.